Gene therapy shows promise for arrhythmogenic cardiomyopathy

Researchers evaluated the effectiveness of adeno-associated virus (AAV)-mediated Plakophilin 2 (PKP2) delivery in treating arrhythmogenic cardiomyopathy (ACM).